New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
November 21, 2012
09:45 EDTARNA, VVUS, OREXVIVUS, Arena, Orexigen move higher in early trading
The makers of obesity drugs are moving higher in early trading. The strength is being attributed to speculation of expanded coverage by insurers.
News For VVUS;ARNA;OREX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
April 15, 2015
19:34 EDTVVUSVIVUS files patent infringement lawsuit against Teva
Subscribe for More Information
April 14, 2015
07:10 EDTVVUSVIVUS says CVOT 'unlikely to initiate' in 2015
Subscribe for More Information
April 10, 2015
08:06 EDTARNAEisai and Arena Pharmaceuticals complete trials of formulation of lorcaserin
Subscribe for More Information
April 7, 2015
09:23 EDTARNAOn The Fly: Pre-market Movers
Subscribe for More Information
08:03 EDTARNAArena Pharmaceuticals receives additional patent for Belviq from USPTO
Arena Pharmaceuticals and Eisai announced that the US Patent and Trademark Office granted Arena US Patent No. 8,999,970, which describes a method for selecting appropriate patients based on renal function for BELVIQ, a serotonin 2C receptor agonist approved for weight management. In addition to this method-of-treatment patent, composition of matter patents for BELVIQ are issued in major jurisdictions globally that, in most cases, are capable of continuing into 2023. Arena has filed applications for patent term extension on patents directed to composition of matter in the United States, which, if granted, would extend the composition of matter patent term for BELVIQ into 2026 or potentially 2027.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use